AKG-PEG Polymeric Microparticles for Bone Regeneration Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related bone loss and large bone defects, such as those caused by trauma or congenital anomalies, face challenges due to the low efficacy of biomaterials like BMP2 and the risks associated with stem cell transplantation, necessitating the development of innovative biomaterials with robust pro-osteogenic properties.
Innovation Solution
A biocompatible polymer comprising a backbone of alpha-ketoglutarate (AKG) and polyethylene glycol (PEG) moieties, which upon hydrolysis releases biologically active compounds, is used to create polymeric microparticles (MPs) for enhancing bone regeneration and osteogenic differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high doses of BMP2 are used to promote bone regeneration, then bone regeneration efficacy is improved, but serious side effects occur
Solution Approach 1:
The patent uses an AKG-based polymeric microparticle system as an intermediary carrier to deliver growth factors and stem cells to bone defect sites. This controlled delivery system allows for localized, sustained release of therapeutic agents at lower doses, avoiding the systemic side effects associated with high-dose BMP2 administration while maintaining effective bone regeneration
Solution Approach 2:
The patent changes the delivery parameters by using biodegradable polymeric microparticles that control the release kinetics of growth factors. This transforms the delivery mode from high-dose bolus administration to low-dose sustained release, improving efficacy while reducing side effects through parameter optimization
2Productivity
If stem cells are transplanted to promote bone regeneration, then bone regeneration is enhanced, but immunological rejection and tumorigenesis risk increase
Solution Approach 1:
The AKG-based polymeric microparticles serve as an intermediary system that delivers stem cells and growth factors to the bone defect site in a controlled manner. This protective carrier system reduces direct immune cell contact with transplanted stem cells, minimizing immunological rejection while maintaining regenerative efficacy and reducing tumorigenesis risk through controlled delivery
Solution Approach 2:
The patent creates a composite delivery system combining biodegradable polymeric materials with stem cells and growth factors. This composite approach allows for synergistic effects where the polymer matrix provides structural support and controlled release, while the biological components deliver therapeutic effects with reduced safety risks
3Productivity
If autologous tissue is used for bone reconstruction, then bone regeneration quality is improved, but availability and donor site morbidity are limited
Solution Approach 1:
The AKG-based polymeric microparticles act as an intermediary that delivers growth factors and stem cells to stimulate local bone formation. This eliminates the need for large quantities of autologous tissue by using the polymer carrier to transport essential regenerative components directly to the defect site, improving availability while maintaining regeneration quality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer-based MPs promote bone regeneration, increase osteogenic differentiation, and enhance intracellular phagocytosis, offering a safer alternative to high-dose BMP2 and reducing the risk of side effects.
Implementation Method 1
the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer
Data Source
AI summary
In certain embodiments, the present invention provides a biocompatible polymer comprising a backbone comprising one or more units of formula (I) in the backbone:wherein A is Alpha-ketoglutarate (AKG); D is 1,8-octanediol (8diol) or 1,10-decanediol (10diol); PEG is polyethylene glycol; and the x: y ratio is between 100 to 200. In certain embodiments, the present invention also provides microparticle compositions and methods of use thereof.